肿瘤细胞治疗研究
英文原题：NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
新型靶向治疗（小分子抑制剂、抗体偶联药物和 CD19 靶向治疗）已改变复发/难治性 B 细胞淋巴瘤的治疗格局。
新型靶向治疗（小分子抑制剂、抗体偶联药物及CD19靶向疗法）改变了复发/难治性B细胞淋巴瘤的治疗格局。布鲁顿酪氨酸激酶（BTK）抑制剂在套细胞淋巴瘤（MCL）复发/难治和一线治疗中的应用仍在不断发展。抗CD19 CAR-T细胞疗法现已成为复发/难治性滤泡性淋巴瘤（FL）、弥漫大B细胞淋巴瘤（DLBCL）及MCL的有效且获批治疗选择。对于经多线治疗（包括既往CAR-T治疗）后的复发性FL和DLBCL，双特异性T细胞接合剂代表一种新的免疫治疗方法。本文《NCCN指南要点》介绍了NCCN B细胞淋巴瘤指南中针对FL、DLBCL和MCL治疗的重要更新。
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
